Skip to content

GRAIL, Inc. GRAL Other Commercial Liabilities

Other Commercial Liabilities at other companies

Guardant Health logo
Guardant HealthGH
Tempus AI, Inc. logo
Tempus AI, Inc.TEM
Adaptive Biotechnologies logo
Adaptive BiotechnologiesADPT
ArriVent BioPharma, Inc. logo
ArriVent BioPharma, Inc.AVBP
GeneDx Holdings logo
GeneDx HoldingsWGS
IDEAYA Biosciences, Inc. logo
IDEAYA Biosciences, Inc.IDYA

Other financials

Income statement

See full
Revenue$40.8M+28.1%
Operating income-$135.8M+11.6%
Net income-$93.2M+12.3%
EPS (diluted)-$2.29+26.1%

Balance sheet

See full
Cash & equivalents$76.3M-44.4%
Total debt$51.0M-20.7%
Total equity$2.5B+3.6%
Total assets$2.8B-1.5%

Cash flow

See full
Operating cash flow-$87.0M+8.4%
CapEx$503.0K+711%
Free cash flow-$87.5M+8.0%

Valuation

See full
Market cap$2.62B+145%
Enterprise value$2.6B+164%
P/S16.8×+8.6×

Profitability

See full
Operating margin-348.7%-153pp
Net margin-253.2%-115pp
FCF margin-187.2%-60.4pp

Returns & leverage

See full
Return on equity-16.1%
Debt / equity0.0×
Current ratio11.7×+2.0×

Where this comes from

Reported directly by GRAIL, Inc. in its filing.

Tagged under the XBRL concept us-gaap:AccruedLiabilitiesCurrent.

The official record: GRAIL, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about GRAIL, Inc.'s other commercial liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is GRAIL, Inc.'s other commercial liabilities?
GRAIL, Inc. (GRAL) reported other commercial liabilities of $58.27M in Q1 2026.
How has GRAIL, Inc.'s other commercial liabilities changed year-over-year?
GRAIL, Inc.'s other commercial liabilities increased by 8.5% year-over-year, from $53.72M to $58.27M.
What is the long-term trend for GRAIL, Inc.'s other commercial liabilities?
Over 2 years (2023 to 2025), GRAIL, Inc.'s other commercial liabilities has grown at a -6.9% compound annual growth rate (CAGR), from $73.71M to $63.95M.